Joshua H. Bilenker, President & CEO at Loxo Oncology, Inc. (LOXO), sold 28,500 shares at $178.81 ($5.1M) on 2018-06-20, disclosed to the SEC on 2018-06-21.
Open-market sale of $5.1M LOXO by President & CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $178.81 | 2,700 | $483K | 9.4% |
| 2 | $178.94 | 11,336 | $2.0M | 39.7% |
| 3 | $179.37 | 4,370 | $784K | 15.3% |
| 4 | $179.77 | 9,664 | $1.7M | 34.0% |
| 5 | $180.90 | 430 | $78K | 1.5% |
| Total | $179.30 avg | 28,500 |
| $5.1M |
| 100% |
| Filing → |
| LOXO | SELL | 2018-12-12 | $2.7M | — | Filing → |
| LOXO | SELL | 2018-12-12 | $1.0M | — | Filing → |
| LOXO | SELL | 2018-11-28 | $1.2M | — | Filing → |